Physician profile
David J Massop
NPI 1003267956
$2,670.55
in general payments reported to CMS, 2019-2025
16 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2021: $150 · 2022: $37.43 · 2023: $208 · 2024: $740 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $623.57 | 2019 | |
| Dutch Ophthalmic, USA | $312.81 | 2024 | Tissueblue, Eva, Combined Machine |
| Regeneron Healthcare Solutions, INC. | $288.82 | 2023-2025 | Eylea Hd, Eylea |
| US Oncology Corporate, INC. | $222.10 | 2025 | |
| Allergan, INC. | $189.32 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $172.32 | 2023-2024 | Eylea, Eylea Hd |
| Alcon Vision LLC | $149.73 | 2021 | |
| Abbvie INC. | $139.68 | 2025 | |
| Genentech USA, INC. | $118.03 | 2024 | Vabysmo |
| Alimera Sciences, INC. | $115.88 | 2019 | |
| Genentech, INC. | $105.55 | 2025 | Vabysmo |
| Bausch & Lomb Americas INC. | $104.72 | 2022-2024 | Xipere, Prolensa, Vyzulta |
| Apellis Pharmaceuticals, INC. | $50.93 | 2023 | Syfovre |
| Neurotech Pharmaceuticals, INC. | $29.86 | 2025 | |
| Harrow Eye, LLC | $26.38 | 2025 | Iheezo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $20.85 | 2025 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Massop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.